他他多使用的风险指标:社区药房个人药物护理方法改善结果的机会

C. R. Armendáriz, Veronica Saray Hernandez Garcia, Daida Alberto Armas, I. Bethencourt, A. H. D. L. Torre
{"title":"他他多使用的风险指标:社区药房个人药物护理方法改善结果的机会","authors":"C. R. Armendáriz, Veronica Saray Hernandez Garcia, Daida Alberto Armas, I. Bethencourt, A. H. D. L. Torre","doi":"10.15406/PPIJ.2021.09.00331","DOIUrl":null,"url":null,"abstract":"Opioids have historically been the pharmacological choice in the treatment of moderate to severe pain of oncological and chronic origin but they have also become a growing and controversial tool in the treatment of non-oncological pain that requires a risk/ benefit evaluation. The present study focuses on the opioid tapentadol, the newest opioid considered highly effective in treating cancer and non-cancer pain. According to the WHO Collaborating Center for Drugs Statistics Methodology, the stated Tapendatol Defined Daily Dose (DDD) for oral administration is 400 mg but the prescribed doses range from 100 mg/day in patients without previous opioid treatments up to a maximum of 600 mg/ day. However, the DDD is a unit of measurement that does not have to reflect the prescribed daily dose (PDD) because therapeutic doses usually differ from DDDs by taking into account individual patient considerations and pharmacokinetic conditions. This retrospective observational study in a community pharmacy on","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk indicators in tapentadol use: opportunities to improve outcomes with a personal pharmaceutical care approach in community pharmacies\",\"authors\":\"C. R. Armendáriz, Veronica Saray Hernandez Garcia, Daida Alberto Armas, I. Bethencourt, A. H. D. L. Torre\",\"doi\":\"10.15406/PPIJ.2021.09.00331\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Opioids have historically been the pharmacological choice in the treatment of moderate to severe pain of oncological and chronic origin but they have also become a growing and controversial tool in the treatment of non-oncological pain that requires a risk/ benefit evaluation. The present study focuses on the opioid tapentadol, the newest opioid considered highly effective in treating cancer and non-cancer pain. According to the WHO Collaborating Center for Drugs Statistics Methodology, the stated Tapendatol Defined Daily Dose (DDD) for oral administration is 400 mg but the prescribed doses range from 100 mg/day in patients without previous opioid treatments up to a maximum of 600 mg/ day. However, the DDD is a unit of measurement that does not have to reflect the prescribed daily dose (PDD) because therapeutic doses usually differ from DDDs by taking into account individual patient considerations and pharmacokinetic conditions. This retrospective observational study in a community pharmacy on\",\"PeriodicalId\":19839,\"journal\":{\"name\":\"Pharmacy & Pharmacology International Journal\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy & Pharmacology International Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/PPIJ.2021.09.00331\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy & Pharmacology International Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/PPIJ.2021.09.00331","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

阿片类药物历来是治疗肿瘤和慢性来源的中度至重度疼痛的药物选择,但它们也成为治疗非肿瘤疼痛的一种日益增长和有争议的工具,需要进行风险/收益评估。目前的研究重点是阿片类药物他他多,最新的阿片类药物被认为对治疗癌症和非癌症疼痛非常有效。根据世卫组织药物统计方法合作中心,规定的口服Tapendatol限定日剂量(DDD)为400毫克,但处方剂量范围从以前未接受过阿片类药物治疗的患者的100毫克/天到最多600毫克/天。然而,DDD是一种测量单位,不必反映处方日剂量(PDD),因为治疗剂量通常与DDDs不同,考虑到个体患者的考虑和药代动力学条件。本回顾性观察研究在社区药房
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Risk indicators in tapentadol use: opportunities to improve outcomes with a personal pharmaceutical care approach in community pharmacies
Opioids have historically been the pharmacological choice in the treatment of moderate to severe pain of oncological and chronic origin but they have also become a growing and controversial tool in the treatment of non-oncological pain that requires a risk/ benefit evaluation. The present study focuses on the opioid tapentadol, the newest opioid considered highly effective in treating cancer and non-cancer pain. According to the WHO Collaborating Center for Drugs Statistics Methodology, the stated Tapendatol Defined Daily Dose (DDD) for oral administration is 400 mg but the prescribed doses range from 100 mg/day in patients without previous opioid treatments up to a maximum of 600 mg/ day. However, the DDD is a unit of measurement that does not have to reflect the prescribed daily dose (PDD) because therapeutic doses usually differ from DDDs by taking into account individual patient considerations and pharmacokinetic conditions. This retrospective observational study in a community pharmacy on
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pilot study to compare the use of the national program drugs ALONE versus their combination with Artemisia Afra infusions for the treatment of pulmonary tuberculosis Gender differences in MS related pain, correlation with MRI lesion localization and burden of disease The efficacy and safety of silodosin-a review of literature Tribenoside–lidocaine combination in wound healing of hemorrhoids: a review of literature The effectively of favipiravir as antiviral therapy in the treatment of covid-19 in the several hospital in Blora, Indonesia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1